首页> 外文期刊>Diabetes >Congenital Hyperinsulinism and Glucose Hypersensitivity in Homozygous and Heterozygous Carriers of Kir6.2 (KCNJ11) Mutation V290M Mutation K_(ATP) Channel Inactivation Mechanism and Clinical Management
【24h】

Congenital Hyperinsulinism and Glucose Hypersensitivity in Homozygous and Heterozygous Carriers of Kir6.2 (KCNJ11) Mutation V290M Mutation K_(ATP) Channel Inactivation Mechanism and Clinical Management

机译:Kir6.2(KCNJ11)纯合子和杂合子携带者的先天性高胰岛素血症和葡萄糖超敏性突变V290M突变K_(ATP)通道失活机制和临床管理

获取原文
获取原文并翻译 | 示例
           

摘要

Objective-the atp-sensitive k~+ channel (k_(atp)) controls insulin secretion from the islet. Gain- or loss-of-function mutations in channel subunits underlie human neonatal diabetes and congenital hyperinsulinism (hi), respectively. In this study, we sought to identify the mechanistic basis of k_(atp)-induced hi in two probands and to characterize the clinical course. Research design and methods-we analyzed hi in two probands and characterized the course of clinical treatment in each, as well as properties of mutant k_(atp) channels expressed in c0sm6 cells using rb efflux and patch-clamp methods. Results-we identified mutation v290m in the pore-forming kir6.2 subunit in each proband. In vitro expression in c0sm6 cells supports the mutation resulting in an inactivating pheno-type, which leads to significantly reduced activity in intact cells when expressed homomerically, and to a lesser extent when expressed heteromerically with wild-type subunits. In one heterozygous proband, a fluoro-dopa scan revealed a causal focal lesion, indicating uniparental disomy with loss of heterozygosity. In a second family, the proband, homozygous for the mutation, was diagnosed with severe diazoxide-unresponsive hypersinsu-linism at 2 weeks of age. The patient continues to be treated successfully with octreotide and amlodipine. The parents and a male sibling are heterozygous carriers without overt clinical hi. Interestingly, both the mother and the sibling exhibit evidence of abnormally enhanced glucose tolerance. Conclusions-v290m results in inactivating katp channels that underlie hi. Homozygous individuals may be managed medically, without pancreatectomy. Heterozygous carriers also show evidence of enhanced glucose sensitivity, consistent with incomplete loss of katp channel activity. Diabetes 60:209-217, 2011
机译:目标-atp敏感的k〜+通道(k_(atp))控制胰岛的胰岛素分泌。通道亚基的功能获得性或功能丧失突变分别是人类新生儿糖尿病和先天性高胰岛素血症(hi)的基础。在这项研究中,我们试图确定两个先证者k_(atp)诱导的hi的机制基础,并表征临床过程。研究设计和方法-我们在两个先证者中进行了hi分析,并对每种方法的临床治疗过程进行了表征,并使用rb外排法和膜片钳方法表征了c0sm6细胞中表达的突变k_(atp)通道的特性。结果-我们在每个先证者的成孔kir6.2亚基中鉴定了突变v290m。在cssm6细胞中的体外表达支持导致失活的表型的突变,当同型表达时,其导致完整细胞中活性的显着降低,而与野生型亚基异源表达时,其活性降低的程度较小。在一个杂合的先证者中,氟多巴扫描显示有病因灶性病变,表明单亲二体性,杂合性丧失。在第二个家庭中,该突变为纯合子的先证者在2周龄时被诊断出患有严重的二氮嗪无反应性高胰岛素血症。继续用奥曲肽和氨氯地平治疗患者。父母和兄弟姐妹是杂合子携带者,没有明显的临床感染。有趣的是,母亲和兄弟姐妹都表现出葡萄糖耐量异常增强的证据。结论-v290m导致hi下方的katp通道失活。纯合子个体可以在不进行胰腺切除的情况下进行医学治疗。杂合子携带者还显示出葡萄糖敏感性增强的证据,这与katp通道活性的不完全丧失相一致。糖尿病60:209-217,2011年

著录项

  • 来源
    《Diabetes》 |2011年第1期|p.209-217|共9页
  • 作者单位

    Department of Pediatrics, University of North Carolina School of Medicine, Chapel Hill, North Carolina;

    Department of Cell Biology and Physiology, Washington University School of Medicine, St. Louis, Missouri;

    Department of Cell Biology and Physiology, Washington University School of Medicine, St. Louis, Missouri;

    Unit of Metabolic Diseases, Department of Pediatrics, Bambino Gesu Children's Hospital, Rome, Italy;

    Unit of Metabolic Diseases, Department of Pediatrics, Bambino Gesu Children's Hospital, Rome, Italy;

    Unit of Nuclear Medicine, Department of Radiology, Bambino Gesu Children's Hospital, Rome, Italy;

    'Depart- ment of Nuclear Medicine, Catholic University of the Sacred Heart, Rome, Italy;

    Department of Surgery, Bambino Gesu Children's Hospital, Rome, Italy;

    Laboratory of Monogenic Diabetes, Bambino Gesu Children's Hospital Istituto Di Ricovero e Cura a Carattere Scientifico, Rome, Italy;

    Laboratory of Monogenic Diabetes, Bambino Gesu Children's Hospital Istituto Di Ricovero e Cura a Carattere Scientifico, Rome, Italy,Department of Internal Medicine, University of Tor Vergata, and Laboratory of Monogenic Diabetes, Bambino Gesu Children's Hospital Istituto Di Ricovero e Cura a Carattere Scientifico, Rome, Italy;

    Department of Cell Biology and Physiology, Washington University School of Medicine, St. Louis, Missouri;

    Department of Cell Biology and Physiology, Washington University School of Medicine, St. Louis, Missouri;

  • 收录信息 美国《科学引文索引》(SCI);美国《化学文摘》(CA);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号